Herzyk DJ - Search Results

1

Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19.

Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M, Rhodes GR. Davis CB, et al. Among authors: herzyk dj. Drug Metab Dispos. 1995 Oct;23(10):1028-36. Drug Metab Dispos. 1995. PMID: 8654189

2

The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers.

Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ, Jorkasky DK. Everitt DE, et al. Among authors: herzyk dj. J Infect Dis. 1996 Sep;174(3):463-9. doi: 10.1093/infdis/174.3.463. J Infect Dis. 1996. PMID: 8769601 Clinical Trial.

3

Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4.

Sharma A, Davis CB, Tobia LA, Kwok DC, Tucci MG, Gore ER, Herzyk DJ, Hart TK. Sharma A, et al. Among authors: herzyk dj. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. J Pharmacol Exp Ther. 2000. PMID: 10734150

4

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, Martin EC, Bugelski PJ, Herzyk DJ. Hart TK, et al. Among authors: herzyk dj. J Allergy Clin Immunol. 2001 Aug;108(2):250-7. doi: 10.1067/mai.2001.116576. J Allergy Clin Immunol. 2001. PMID: 11496242

5

Preclinical safety of recombinant human interleukin-18.

Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ. Herzyk DJ, et al. Toxicol Pathol. 2003 Sep-Oct;31(5):554-61. doi: 10.1080/01926230390226681. Toxicol Pathol. 2003. PMID: 14692624

6

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

Bugelski PJ, Herzyk DJ, Rehm S, Harmsen AG, Gore EV, Williams DM, Maleeff BE, Badger AM, Truneh A, O'Brien SR, Macia RA, Wier PJ, Morgan DG, Hart TK. Bugelski PJ, et al. Among authors: herzyk dj. Hum Exp Toxicol. 2000 Apr;19(4):230-43. doi: 10.1191/096032700678815783. Hum Exp Toxicol. 2000. PMID: 10918514

7

Practical aspects of including functional endpoints in developmental toxicity studies. Case study: immune function in HuCD4 transgenic mice exposed to anti-CD4 MAb in utero.

Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ. Herzyk DJ, et al. Hum Exp Toxicol. 2002 Sep-Oct;21(9-10):507-12. doi: 10.1191/0960327102ht289oa. Hum Exp Toxicol. 2002. PMID: 12458908

8

Flow cytometry in the preclinical development of biopharmaceuticals.

Gossett KA, Narayanan PK, Williams DM, Gore ER, Herzyk DJ, Hart TK, Sellers TS. Gossett KA, et al. Among authors: herzyk dj. Toxicol Pathol. 1999 Jan-Feb;27(1):32-7. doi: 10.1177/019262339902700107. Toxicol Pathol. 1999. PMID: 10367670 Review.

9

Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice.

Herzyk DJ, Gore ER, Polsky R, Nadwodny KL, Maier CC, Liu S, Hart TK, Harmsen AG, Bugelski PJ. Herzyk DJ, et al. Infect Immun. 2001 Feb;69(2):1032-43. doi: 10.1128/IAI.69.2.1032-1043.2001. Infect Immun. 2001. PMID: 11160000 Free PMC article.

10

Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species.

Ruggieri EV, Bugelski PJ, Kaplan JM, Everitt D, Lipani J, Jorkasky DK, Boike SC, DeClement F, Moore FD Jr, Herzyk DJ. Ruggieri EV, et al. Among authors: herzyk dj. J Clin Immunol. 1996 Mar;16(2):97-106. doi: 10.1007/BF01540956. J Clin Immunol. 1996. PMID: 8690778

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters